Trial · NCT00544778
Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma
NCT00544778, Phase 2, Terminated, City of Hope Medical Center; results first posted 2014-08-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma. Trials, record NCT00544778. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00544778
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma
- NCT number
- NCT00544778
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- City of Hope Medical Center
- Conditions
- Sarcoma
- Interventions
filgrastim, dexrazoxane hydrochloride, doxorubicin hydrochloride, ifosfamide, irinotecan hydrochloride, protein expression analysis, immunoenzyme technique, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
- First posted
- 2007-10-16
- Last updated
- 2014-08-28
- Results first posted
- 2014-08-28
- Limitations and caveats
The study was terminated…protocol objectives not met. It was closed prematurely due to withdrawal of support by the sponsor. Subjects have been followed, but there is not enough data generated to continue following the subjects.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | First disease evaluation one month after the start of treatment and every 3 months there after, up to 2 years. | Response rate defined as the proportion of subjects with confirmed partial or complete response as defined by the RECIST criteria. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | First disease evaluation one month after the start of treatment and every 3 months there after, up to 2 years. | percentage of patients responding | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Arm 1 | 0 | percentage of patients responding |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1 | 7 | |
| Overall Study | COMPLETED | Arm 1 | 7 | |
| Overall Study | NOT COMPLETED | Arm 1 | 0 |
Source ClinicalTrials.gov
Adverse events69
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm 1 | 4 | 7 | 5 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Arm 1 | 6 | 7 | 21 |
| other | Packed red blood cell transfusion | Blood and lymphatic system disorders | Arm 1 | 3 | 7 | 5 |
| other | Sinus tachycardia | Cardiac disorders | Arm 1 | 3 | 7 | 5 |
| other | Vision blurred | Eye disorders | Arm 1 | 1 | 7 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Arm 1 | 4 | 7 | 4 |
| other | Constipation | Gastrointestinal disorders | Arm 1 | 4 | 7 | 6 |
| other | Diarrhea | Gastrointestinal disorders | Arm 1 | 3 | 7 | 4 |
| other | Dyspepsia | Gastrointestinal disorders | Arm 1 | 4 | 7 | 5 |
| other | Esophagitis | Gastrointestinal disorders | Arm 1 | 1 | 7 | 1 |
1 to 10 of 69Source ClinicalTrials.gov
See all 69 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 | ||
| Total, other adverse events | Arm 1 | 6 | 7 |
| Total, serious adverse events | Arm 1 | 0 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA033572 | Cancer Center Support Grant | CARPTEN, JOHN D. | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00544778
GET https://conductscience.org/api/trials/v1/NCT00544778/events?page=2